In four studies limited to NSCLC, compared to the controls without PD-1/PD-L1 inhibitors, greater benefit was found in the non-smokers’ group (HR(Non-smoker) vs. HR(Smoker) = 0.45 vs. 0.72). Here, CD274 is linked to non-small cell lung carcinoma.